Second Phase 3 Study of MDMA-assisted Therapy Reports Positive Results, Paving Way for New Drug Application Post published:September 14, 2023 Post category:News
Confirmatory Phase 3 Trial of MDMA Therapy for PTSD is “Successful”, Says MAPS Post published:January 5, 2023 Post category:Announcements
MAPS Wraps Second Phase 3 Trial of MDMA-Assisted Therapy for PTSD Post published:November 17, 2022 Post category:News/Press Release
Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial Post published:December 2, 2020 Post category:Press Release
MAPS Study: MDMA-Assisted Psychotherapy Will Be More Cost-Effective than Other Treatments for PTSD Post published:October 27, 2020 Post category:Press Release
Psychedelic Research Fundraising Campaign Attracts $30 Million in Donations in 6 Months, Prepares MDMA-Assisted Psychotherapy for FDA Approval Post published:August 20, 2020 Post category:Press Release
MAPS announces $30m, 90-day Capstone Challenge to Finalise MDMA as Medicine for PTSD; Tim Ferriss Donates $1m Post published:June 21, 2020 Post category:News